BioNTech to pay $1.2 billion over vaccine royalties
Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
Last year, Moderna ( NASDAQ: MRNA) made headlines with its individualized mRNA cancer vaccine mRNA-4157 (V940), developed ...
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...
The ADR's fall snapped a three-day winning streak.
Recent health news includes the FDA's approval of an injectable version of Opdivo, a revived lawsuit against Novartis for ...
South Korea's parliament impeached acting President Han Duck-soo on Friday, less than two weeks after suspending President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback